Monoclonal Antibodies
NGM707 + Pembrolizumab for Cancer
Recruiting1 awardPhase 1 & 2
Grand Rapids, Michigan
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
Cancer Vaccine
ELI-002 Immunotherapy for Pancreatic Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is testing a new immunotherapy called ELI-002. It targets patients with specific genetic mutations in their cancer. The treatment works by helping the immune system recognize and attack these cancer cells.
Popular Filters
Trials for CCA Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
Recruiting2 awardsPhase 1 & 2
San Francisco, California
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
Trials for Bile Duct Cancer Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
Recruiting2 awardsPhase 1 & 2
San Francisco, California
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
Trials for Metastatic Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
Recruiting2 awardsPhase 1 & 2
San Francisco, California
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Trials for FGFR2 Positive Patients
Tyrosine Kinase Inhibitor
RLY-4008 for Bile Duct Cancer
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is testing a new drug called RLY-4008 in patients with hard-to-treat cancers that can't be removed by surgery or have spread. The drug works by blocking a protein that helps cancer cells grow.
FGFR Inhibitor
Tinengotinib for Bile Duct Cancer
Recruiting2 awardsPhase 3
Santa Monica, California
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Tyrosine Kinase Inhibitor
Afatinib + Pemigatinib for Solid Tumors
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing if a combination of two drugs, Afatinib and Pemigatinib, is safe and effective for treating certain types of advanced solid tumors with specific genetic mutations. The study
Alkylating agents
Pemigatinib vs Chemotherapy for Bile Duct Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing a new drug called pemigatinib against the usual cancer treatment. It focuses on patients with advanced bile duct cancer who have a specific change in their genes. The goal is to see if pemigatinib is more effective and safer than the usual treatment. Pemigatinib is the first of its kind approved in the US, receiving approval recently.
Trials for IDH Positive Patients
PARP Inhibitor
Olaparib for Advanced Cancer
Recruiting1 awardPhase 2
Costa Mesa, California
This trial will study how well olaparib works in treating patients with certain types of cancer that have spread and usually cannot be controlled with treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
IDH1 Inhibitor
Ivosidenib + Durvalumab + Chemotherapy for Cholangiocarcinoma
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial aims to test the safety and effectiveness of a drug called ivosidenib in combination with durvalumab and gemcitabine/cisplatin as a first-line treatment for participants
Trials With No Placebo
CAR T-cell Therapy
Cell Therapy for Mesothelioma
Recruiting2 awardsPhase 1 & 2
San Francisco, California
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.